ABSTRACT This study investigated the efficacy and safety of a novel thermo‐reversible antimicrobial wound gel (TRG, revyve Antimicrobial Wound Gel) designed to combat biofilm‐related infections in wounds. The TRG was evaluated for its ability to disrupt biofilms, sustain antimicrobial activity and promote wound healing. The gel exhibited thermo‐reversible properties, transitioning from a less viscous liquid ≤ 18°C to a highly viscous solid gel at wound temperature which would facilitate easy application and removal. Antimicrobial testing demonstrated that TRG effectively inactivated a broad range of wound‐related pathogens, including Staphylococcus aureus and Pseudomonas aeruginosa , with a 99.99%–99.9999% reduction in bacterial counts within 30 min. The TRG also maintained its antimicrobial efficacy after multiple inoculations with high microbial load (10 7 CFU/mL) over 7 days. In vitro biofilm assays showed effectiveness against biofilm bacteria with a reduction of ≥ 99.99% bacterial counts with one application over the course of 7 days. Biocompatibility testing confirmed that TRG was safe, with no signs of tissue necrosis or signs of tissue damage and no impact on wound healing in a porcine wound model. TRG's ability to reduce both planktonic and biofilm‐based bacteria without compromising wound healing makes it a promising candidate for treating both chronic and acute wounds.
Visvalingam et al. (Sun,) studied this question.